BioPharmSignal logoBioPharmSignal

Biotech News

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

DiaMedica Therapeutics (DMAC)DiaMedica TherapeuticsFDA / regulatory

DMAC (DMAC) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is dmac.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

DMACDiaMedica Therapeutics2026-06-16 12:30 EST

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

DMACDiaMedica Therapeutics2026-03-05 12:35 EST

DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

View all latest news

DiaMedica Therapeutics

Recombinant Kallikrein Therapy DiaMedica Therapeutics develops DM199, a recombinant form of human tissue kallikrein intended to restore biological pathways involved in vascular regulation, placental function and tissue perfusion. Preeclampsia Program Multiple Phase 2 studies are evaluating DM199 in early-onset preeclampsia. These studies...

Recent company news

DMACDiaMedica Therapeutics2026-08-10 20:30 EST

DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

DMACDiaMedica Therapeutics2026-08-04 20:30 EST

DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026

DMACDiaMedica Therapeutics2026-07-17 20:30 EST

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DMACDiaMedica Therapeutics2026-06-23 12:30 EST

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

DMACDiaMedica Therapeutics2026-06-16 12:30 EST

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program

Stock data

Close
6.52 USD
Market cap
310.91M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States